Patient Counseling, Drug Utilization Review, and Patient Safety
Prospective and retrospective DUR
Prospective review happens before the product leaves the pharmacy: therapeutic duplication, drug–drug and drug–disease interactions, allergy cross-sensitivity, dose and duration appropriateness, and abuse or misuse signals. Retrospective review looks back across claims or profiles. Both are documented. A problem identified but not documented looks, on inspection, like a problem never found.
Counseling
Every new prescription warrants an offer to counsel, and counseling itself is a pharmacist function. Content covers name and description of the drug, dosage form and route, dose and administration, expected duration, special directions and precautions, common adverse effects and what to do about them, interactions, self-monitoring, storage, and what to do if a dose is missed. Refusals are documented. Counseling should occur in an area offering privacy and in a language the patient understands, with interpreter services where needed.
Patient safety infrastructure
High-alert medications (anticoagulants, insulin, opioids, concentrated electrolytes, chemotherapy) warrant independent double checks. Look-alike/sound-alike names, tall-man lettering, and dose-range checks reduce selection error. Errors are reported internally and externally as required (MedWatch for product problems, institutional reporting for hospitals). REMS drugs carry counseling and documentation obligations layered on top of ordinary counseling. Naloxone co-dispensing and standing-order naloxone are core harm-reduction tools.
Traps
- Assuming a technician may deliver the substantive counseling content.
- Assuming a one-time blanket waiver signed at intake covers every future prescription.
- Forgetting that an intervention must be documented, including the prescriber's response.
Rule of thumb: counsel on every new prescription, offer on every refill, and document refusals.
Worked example: a patient stable on warfarin presents a new prescription for trimethoprim-sulfamethoxazole. Prospective DUR flags a significant interaction. The pharmacist contacts the prescriber, documents the recommendation (alternative agent or added INR monitoring), and records the outcome before dispensing.